<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35067505</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1536-7355</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>28</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases</Title>
          <ISOAbbreviation>J Clin Rheumatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Prevalent Drug Usage Practices in Adults and Children With Idiopathic Inflammatory Myopathies: Registry-Based Analysis From the MyoCite Cohort.</ArticleTitle>
        <Pagination>
          <StartPage>89</StartPage>
          <EndPage>96</EndPage>
          <MedlinePgn>89-96</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/RHU.0000000000001813</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Idiopathic inflammatory myopathies (IIMs) form a heterogeneous group of disorders with a deficit of quality evidence regarding its management. Therefore, we aimed to explore the prevalent treatment practices in the MyoCite cohort from India.</AbstractText>
          <AbstractText Label="METHODS">Drug usage patterns, their predictors, drug retention rates, efficacy, and adverse drug reactions were analyzed for adults and children newly diagnosed with IIM (2017-2020) and followed prospectively and compared with real-world data by performing a medical records review. GraphPad Prism version 8.4.2 was used for statistical analysis.</AbstractText>
          <AbstractText Label="RESULTS">Of 181 adults (male-to-female ratio, 1:4.6) and 30 children (M:F, 1.3:1), dermatomyositis (41% adults, 93% children) was the most common subtype. Methotrexate (MTX) was the drug of choice (67% adult, 90% children) followed by azathioprine (AZA) and mycophenolate mofetil (MMF). The MMF, AZA, cyclophosphamide, and rituximab (RTX) were preferred for those with antisynthetase syndrome (ASSD) and those with lung involvement, whereas MTX was avoided in them. Functional class and family income did not determine drug preferences. Glucocorticoids were initiated at a lower dose in overlap myositis (45% vs 80%, p = 0.001), and the time to achieve the lowest dose of glucocorticoids was longer than 24 months for ASSD (77% vs 14%, p = 0.002).Over a median of 35 months, the overall retention rate was the highest for RTX (75%) followed by MTX (58%). Relapse-free survival was the highest for RTX followed by MTX. The most common reasons for discontinuation were adverse drug reactions for MTX and MMF, inefficacy for AZA, and cost for RTX.</AbstractText>
          <AbstractText Label="CONCLUSIONS">In this first analysis of drug usage and retention in patients with IIM in Northern India, MTX emerged as the most preferred drug in both adults and children, with the exception of those with ASSD or lung disease. Organ involvement and subtype of IIM are key determinants of drug preference. Overall, RTX and MTX were well-tolerated with high retention rates, followed by AZA and MMF.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mehta</LastName>
            <ForeName>Pankti</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rathore</LastName>
            <ForeName>Upendra</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Naveen</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chatterjee</LastName>
            <ForeName>Rudrarpan</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Agarwal</LastName>
            <ForeName>Vikas</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aggarwal</LastName>
            <ForeName>Rohit</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Pittsburgh, Pittsburgh, PA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gupta</LastName>
            <ForeName>Latika</ForeName>
            <Initials>L</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Rheumatol</MedlineTA>
        <NlmUniqueID>9518034</NlmUniqueID>
        <ISSNLinking>1076-1608</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>HU9DX48N0T</RegistryNumber>
          <NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>MRK240IY2L</RegistryNumber>
          <NameOfSubstance UI="D001379">Azathioprine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001379" MajorTopicYN="N">Azathioprine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009220" MajorTopicYN="Y">Myositis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004364" MajorTopicYN="Y">Pharmaceutical Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>5</Hour>
          <Minute>48</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35067505</ArticleId>
        <ArticleId IdType="doi">10.1097/RHU.0000000000001813</ArticleId>
        <ArticleId IdType="pii">00124743-202203000-00006</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lundberg IE, Miller FW, Tjärnlund A, et al. Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med. 2016;280:39–51. doi:10.1111/joim.12524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/joim.12524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Betteridge Z, Tansley S, Shaddick G, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48–55. doi:10.1016/j.jaut.2019.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2019.04.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018;14:290–302. doi:10.1038/nrrheum.2018.56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrrheum.2018.56</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oddis CV. Update on the pharmacological treatment of adult myositis. J Intern Med. 2016;280:63–74. doi:10.1111/joim.12511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/joim.12511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phillippi K, Hoeltzel M, Byun Robinson A, et al; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry Investigators. Race, income, and disease outcomes in juvenile dermatomyositis. J Pediatr. 2017;184:38–44.e1. doi:10.1016/j.jpeds.2017.01.046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpeds.2017.01.046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall JC, Casciola-Rosen L, Samedy L-A, et al. Anti-MDA5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013;65:1307–1315. doi:10.1002/acr.21992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acr.21992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta L, Appani SK, Janardana R, et al. Meeting report: MyoIN–Pan-India collaborative network for myositis research. Indian J Rheumatol. 2019;14:136. doi:10.4103/injr.injr_40_19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/injr.injr_40_19</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehta P, Gupta L. Combine case record forms for collaborative datasets of patients and controls of idiopathic inflammatory myopathies. Indian J Rheumatol. 2020;15:191–193. doi:10.4103/injr.injr_56_20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/injr.injr_56_20</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naveen R, Anuja AK, Rai MK, et al. Development of the myocite biobank: cost-efficient model of public sector investigator-driven biobank for idiopathic inflammatory myositis. Indian J Rheumatol. 2020;15:194–199. doi:10.4103/injr.injr_95_20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/injr.injr_95_20</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>STROBE Statement: Home. Available at: https://www.strobe-statement.org/index.php?id=strobe-home. Accessed August 16, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Bottai M, Tjärnlund A, Santoni G, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017;3:e000507. doi:10.1136/rmdopen-2017-000507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/rmdopen-2017-000507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nuño-Nuño L, Joven BE, Carreira PE, et al. Overlap myositis, a distinct entity beyond primary inflammatory myositis: a retrospective analysis of a large cohort from the REMICAM registry. Int J Rheum Dis. 2019;22:1393–1401. doi:10.1111/1756-185X.13559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1756-185X.13559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Connors GR, Christopher-Stine L, Oddis CV, et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?Chest. 2010;138:1464–1474. doi:10.1378/chest.10-0180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.10-0180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahler M, Betteridge Z, Bentow C, et al. Comparison of three immunoassays for the detection of myositis specific antibodies. Front Immunol. 2019;10:848. doi:10.3389/fimmu.2019.00848.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.00848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Response to: ‘Semi-quantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance?’ by Cavazzana et al |. Annals of the Rheumatic Diseases. Available at: https://ard.bmj.com/content/early/2019/07/15/annrheumdis-2019-215967. Accessed August 10, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Mehta P, Agarwal V, Gupta L. High early mortality in idiopathic inflammatory myopathies: results from the inception cohort at a tertiary Care Centre in Northern India. Rheumatology (Oxford). 2021;60:4281–4290. doi:10.1093/rheumatology/keab001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/keab001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta L, Naveen R, Gaur P, et al. Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis. Semin Arthritis Rheum. 2021;51:113–120. doi:10.1016/j.semarthrit.2020.10.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semarthrit.2020.10.014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94:379–387. doi:10.1016/0002-9343(93)90148-i.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0002-9343(93)90148-i</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman ED, Scott DW. The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J Clin Rheumatol. 1995;1:99–102. doi:10.1097/00124743-199504000-00007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00124743-199504000-00007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci. 1951;221:176–182.</Citation>
        </Reference>
        <Reference>
          <Citation>Ledingham J, Gullick N, Irving K, et al. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology (Oxford). 2017;56:2257. doi:10.1093/rheumatology/kew479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kew479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fragoulis GE, Conway R, Nikiphorou E. Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature. Rheumatology (Oxford). 2019;58:1900–1906. doi:10.1093/rheumatology/kez337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kez337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huapaya JA, Silhan L, Pinal-Fernandez I, et al. Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease. Chest. 2019;156:896–906. doi:10.1016/j.chest.2019.05.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chest.2019.05.023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res. 2010;62:1496–1501. doi:10.1002/acr.20212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acr.20212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40:640–646. doi:10.3899/jrheum.121043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.121043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aggarwal R, Cassidy E, Fertig N, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014;73:227–232. doi:10.1136/annrheumdis-2012-201800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2012-201800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314–324. doi:10.1002/art.37754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.37754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford). 2015;54:1420–1428. doi:10.1093/rheumatology/kev004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kev004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allenbach Y, Guiguet M, Rigolet A, et al. Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label, phase II trial. PloS One. 2015;10:e0133702. doi:10.1371/journal.pone.0133702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0133702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yadavar S (2019) 90% Of India's Poorest Have No Health Insurance. Available at: https://www.indiaspend.com/90-of-indias-poorest-have-no-health-insurance/. Accessed September 4, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Dalal DS, Zhang T, Shireman TI. Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2020;50:822–826. doi:10.1016/j.semarthrit.2020.08.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semarthrit.2020.08.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mittal S, Naidu GSRSNK, Jha S, et al. Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis-a real-life experience. Clin Rheumatol. 2021;40:645–651. doi:10.1007/s10067-020-05261-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-020-05261-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoo DH, Suh CH, Shim SC, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:566–570. doi:10.1136/annrheumdis-2016-209540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2016-209540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qureshi ZP, Magwood JS, Singh S, et al. Rituximab and biosimilars—equivalence and reciprocity. Biosimilars. 2013;2013:19–25. doi:10.2147/BS.S20681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/BS.S20681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72:1280–1286. doi:10.1136/annrheumdis-2012-202844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2012-202844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rider LG, Lachenbruch PA, Monroe JB, et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum. 2009;60:3425–3435. doi:10.1002/art.24904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.24904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malaviya idiopathic inflammatory myopathies: contributions from India. Available at: https://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=6;spage=209;epage=216;aulast=Malaviya. Accessed September 19, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis–associated interstitial lung disease. N Engl J Med. 2019;381:291–293. doi:10.1056/NEJMc1900045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1900045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paik JJ, Casciola-Rosen L, Shin JY, et al. Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients. Arthritis Rheumatol. 2021;73:858–865. doi:10.1002/art.41602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.41602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshifuji H, Fujii T, Kobayashi S, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006;39:233–241. doi:10.1080/08916930600622884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08916930600622884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lie E, van der Heijde D, Uhlig T, et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:671–676. doi:10.1136/ard.2009.113308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2009.113308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review. The Journal of Rheumatology. Available at: https://www.jrheum.org/content/43/11/1997. Accessed September 4, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Juge PA, Lee JS, Lau J, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021;57:2000337. doi:10.1183/13993003.00337-2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.00337-2020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387:671–678. doi:10.1016/S0140-6736(15)01021-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(15)01021-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobs JC. Methotrexate and azathioprine treatment of childhood dermatomyositis. Pediatrics. 1977;59:212–218.</Citation>
        </Reference>
        <Reference>
          <Citation>Riley P, Maillard SM, Wedderburn LR, et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004;43:491–496. doi:10.1093/rheumatology/keh082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/keh082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tansley SL, McHugh NJ, Wedderburn LR. Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?Arthritis Res Ther. 2013;15:211. doi:10.1186/ar4198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar4198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu K, Tomlinson G, Reed AM, et al. Pilot study of the juvenile dermatomyositis consensus treatment plans: a CARRA registry study. J Rheumatol. 2021;48:114–122. doi:10.3899/jrheum.190494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.190494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellutti Enders F, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76:329–340. doi:10.1136/annrheumdis-2016-209247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2016-209247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huber AM, Robinson AB, Reed AM, et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken). 2012;64:546–553. doi:10.1002/acr.20695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acr.20695</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
